Caxton Associates LLP Purchases Shares of 51,764 Pacira BioSciences, Inc. $PCRX

Key Points

• Caxton Associates LLP acquired 51,764 shares of Pacira BioSciences, valued at approximately $1.29 million, during the first quarter, holding about 0.11% of the company.
• Insider activity includes Marcelo Bigal, a director, selling 4,912 shares, resulting in a 30.13% decrease in his ownership of the stock.
• Pacira BioSciences recently reported an earnings per share (EPS) of $0.74, slightly exceeding analysts' expectations, while its stock has seen fluctuation with a current share price of $26.30.

Caxton Associates LLP purchased a new stake in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) during the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 51,764 shares of the company's stock, valued at approximately $1,286,000. Caxton Associates LLP owned approximately 0.11% of Pacira BioSciences as of its most recent SEC filing.

Other hedge funds also recently made changes to their positions in the company. Caitong International Asset Management Co. Ltd bought a new stake in shares of Pacira BioSciences during the first quarter valued at approximately $51,000. Brooklyn Investment Group raised its stake in Pacira BioSciences by 372.2% during the first quarter. Brooklyn Investment Group now owns 2,238 shares of the company's stock valued at $56,000 after buying an additional 1,764 shares during the last quarter. US Bancorp DE raised its stake in Pacira BioSciences by 31.0% during the first quarter. US Bancorp DE now owns 2,270 shares of the company's stock valued at $56,000 after buying an additional 537 shares during the last quarter. Wealthquest Corp purchased a new position in Pacira BioSciences during the first quarter valued at $59,000. Finally, GAMMA Investing LLC raised its stake in Pacira BioSciences by 112.8% during the first quarter. GAMMA Investing LLC now owns 3,694 shares of the company's stock valued at $92,000 after buying an additional 1,958 shares during the last quarter. 99.73% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of brokerages have issued reports on PCRX. Zacks Research upgraded Pacira BioSciences from a "strong sell" rating to a "hold" rating in a research note on Thursday, August 14th. Wall Street Zen upgraded Pacira BioSciences from a "hold" rating to a "buy" rating in a research note on Friday, June 6th. Finally, Truist Financial upgraded Pacira BioSciences from a "hold" rating to a "buy" rating and set a $30.00 price objective for the company in a research note on Friday, July 25th. Five analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat.com, Pacira BioSciences presently has a consensus rating of "Moderate Buy" and an average target price of $30.83.

Pacira BioSciences Stock Up 0.3%

Shares of PCRX stock traded up $0.09 during mid-day trading on Friday, hitting $27.12. The company's stock had a trading volume of 601,903 shares, compared to its average volume of 604,000. The stock has a market cap of $1.22 billion, a price-to-earnings ratio of -9.76 and a beta of 0.42. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.91 and a current ratio of 2.38. Pacira BioSciences, Inc. has a 52-week low of $12.84 and a 52-week high of $27.64. The business has a 50-day moving average price of $24.31 and a 200 day moving average price of $24.63.

Pacira BioSciences (NASDAQ:PCRX - Get Free Report) last posted its quarterly earnings data on Tuesday, August 5th. The company reported $0.74 EPS for the quarter, beating analysts' consensus estimates of $0.73 by $0.01. The company had revenue of $181.10 million during the quarter, compared to analysts' expectations of $183.11 million. Pacira BioSciences had a positive return on equity of 13.29% and a negative net margin of 18.08%.Pacira BioSciences's revenue for the quarter was up 1.7% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.96 earnings per share. Pacira BioSciences has set its FY 2025 guidance at EPS. Research analysts predict that Pacira BioSciences, Inc. will post 2.41 EPS for the current fiscal year.

Insider Buying and Selling

In related news, Director Marcelo Bigal sold 4,912 shares of the company's stock in a transaction on Thursday, August 7th. The stock was sold at an average price of $23.67, for a total transaction of $116,267.04. Following the completion of the sale, the director owned 11,393 shares in the company, valued at approximately $269,672.31. This represents a 30.13% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 6.40% of the company's stock.

About Pacira BioSciences

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients' journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.